Bard C R Inc /nj/ (BCR): Timothy M Ring , Chairman and CEO of Bard C R Inc /nj/ sold 110,000 shares on Sep 23, 2016. The Insider selling transaction was reported by the company on Sep 27, 2016 to the Securities and Exchange Commission. The shares were sold at $228.90 per share for a total value of $25185094 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 20, 2016, Betty D Larson (VP – Human Resources) sold 4,032 shares at $225.66 per share price.On Sep 8, 2016, Samrat S. Khichi (Sr. VP, Gen Counsel & Secy.) sold 9,183 shares at $221.21 per share price.Also, On Sep 8, 2016, John A Deford (Sr. VP Sci Tech and Clin Afrs) sold 7,928 shares at $221.30 per share price.On Jun 1, 2016, Christopher S Holland (Senior Vice President and CFO) sold 3,970 shares at $219.88 per share price.
C R Bard Inc: On Thursday, Sep 22, 2016 heightened volatility was witnessed in C R Bard Inc which led to swings in the share price. The shares opened for trading at $228.73 and hit $232 on the upside , eventually ending the session at $231.35, with a gain of 1.24% or 2.84 points. The heightened volatility saw the trading volume jump to 4,35,705 shares. The 52-week high of the share price is $239.4299 and the company has a market cap of $16,994 M . The 52-week low of the share price is at $172.21.
Company has been under the radar of several Street Analysts.C R Bard Inc is Upgraded by Wells Fargo to Outperform. Earlier the firm had a rating of Market Perform on the company shares. The Rating was issued on Sep 16, 2016.C R Bard Inc is Reiterated by Deutsche Bank to Hold and the brokerage firm has raised the Price Target to $ 240 from a previous price target of $234 .The Rating was issued on Jul 27, 2016.C R Bard Inc is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 235 from a previous price target of $224 .The Rating was issued on Jul 27, 2016.C R Bard Inc is Downgraded by BofA/Merrill to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Jul 8, 2016.
C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.